Novo Nordisk announced today the launch of NovoCare® Pharmacy, a direct-to-patient service offering all doses of its FDA-approved weight-loss drug Wegovy® (semaglutide) at a reduced monthly cost of $499 for cash-paying patients. The program includes home delivery and targets uninsured individuals or those whose commercial insurance does not cover obesity treatments.
Key Details
- Affordable Access: The 499/monthpricecoversallWegovy®doses(0.25mgto2.4mg),addressingfinancialbarriersforcash−payingpatients.Over90499/monthpricecoversallWegovyR◯doses(0.25mgto2.4mg),addressingfinancialbarriersforcash−payingpatients.Over900–$25 monthly.
- Home Delivery: Prescriptions are fulfilled by CenterWell Pharmacy, a specialty pharmacy recognized for patient satisfaction. Shipments include refill reminders and live case manager support.
- Safety Focus: The move aims to combat risks linked to counterfeit or compounded semaglutide products, which lack FDA approval. Wegovy®’s formulation and safety are backed by rigorous clinical trials.
- FDA Shortage Resolved: The launch follows the FDA’s confirmation that Wegovy® supply now meets U.S. demand after years of shortages.
Program Eligibility
The service is available to:
- Uninsured patients.
- Insured patients without obesity medication coverage.
- Individuals prescribed Wegovy® for weight management or cardiovascular risk reduction in adults with obesity/overweight.
Safety Warnings
Wegovy® carries a Boxed Warning for thyroid tumor risks, including cancer, observed in animal studies. Other serious side effects may include pancreatitis, gallbladder issues, kidney problems, and low blood sugar. Patients are urged to discuss medical history with providers before use.
Broader Impact
“NovoCare® Pharmacy reflects our commitment to equitable access,” said Dave Moore, Novo Nordisk U.S. Operations Lead. “By combining affordability with reliable home delivery, we’re empowering patients to avoid unsafe alternatives.”
The company plans to extend the $499 pricing to retail pharmacies soon.
About Wegovy®
Wegovy® is an injectable GLP-1 receptor agonist approved for:
- Chronic weight management in adults and children over 12 with obesity.
- Reducing cardiovascular risks in adults with heart disease and obesity/overweight.
Company Backgrounds
- Novo Nordisk: A global healthcare leader in diabetes and obesity treatments, headquartered in New Jersey.
- CenterWell: A Humana Inc. subsidiary specializing in senior-focused primary care, home health, and pharmacy services.
For more details, visit NovoCare.com or review Wegovy®’s safety information here.
Source: Novo Nordisk Inc.